Compare Gap Inc (GAP) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Gap Inc trades at $23.53 (market cap $8.02B), while Travere Therapeutics Inc. Common Stock trades at $54.93 (market cap $5.02B). The key difference: Gap Inc is the larger of the two by market cap, and Gap Inc pays a 3.07% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| GAP | TVTX | |
|---|---|---|
Market Cap | $8.02B | $5.02B |
Volume | 4,496,595 | 2,060,842 |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $67.52 |
52-Week Low | $18.35 | $26.79 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $11.25B | $5.15B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap Inc. (GAP) trades at $22.83, up 0.22% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 43.26% gross margin and 33.78% ROE, supported by recent earnings beats. Valuation metrics appear attractive with a P/E of 6.88 and P/S of 0.56. Recent developments include a 'fashiontainment' partnership with boy band JYT and board appointments, signaling strategic brand revitalization efforts.
The outlook is positive given low valuation, earnings momentum, and strategic initiatives, but risks include brand execution and Old Navy's sales decline. Analyst consensus is a $25.67 price target with a 'Hold' bias, reflecting cautious optimism amid transformation efforts.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
